Ruben Mesa, MD of the Mayo Clinic, Phoenix, AZ talks about several key ongoing trials for the treatment of myelofibrosis. Prof. Mesa mentions two large Phase III studies of momelotinib in myelofibrosis; SIMPLIFY-1 (NCT01969838) is an up-front study of momelotinib versus ruxolitinib, and SIMPLIFY-2, which is a second-line study (NCT02101268). Other studies include one large study with anti-fibrosing agent called PRM-151, that works against the fibrosing process; results are anticipated with great interest to see the depth of response. Also, imetelstat is being tested in a range of individuals with myelofibrosis who have failed ruxolitinib, comparing them at different dose levels. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates